Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Activists get their way as Ariad CEO Berger steps down

Activist investor Alex Denner has called off his proxy fight with Ariad Pharmaceuticals, a cease-fire that appears to have cost Harvey Berger, the biotech's founder and CEO, his job.

Keryx selects John Neylan for newly created CMO role

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Allergan to cut loose 577 more workers in Irvine

The pink slips are flying at Allergan once again. Recently bought by Actavis in a $66 billion deal, the company is preparing to lay off 577 more workers in a cost-cutting drive that started last year and won't end till its new head honchos finish squeezing savings out of the combined company.

Drew Fromkin tapped to lead Langer's Blend Therapeutics

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Jeremy Levin's back, building a rare-disease biotech with failed drugs

Former Teva CEO Jeremy Levin has taken the pilot's seat at a stealth biotech devoted to rare brain diseases and is piloting a course straight into the industry spotlight.

Takeda taps Lilly exec to run U.S. unit, adding a woman to its all-male exec team

Takeda has chosen a woman to run its U.S. pharma business, just weeks after new CEO Christophe Weber said he was unhappy with the gender balance in the Japanese drugmaker's management ranks. Weber recruited Eli Lilly USA exec Ramona Sequeira to replace Doug Cole, who announced his departure last November.

Merck's Frazier joins top-paid pharma CEOs with a $25M package

Thanks to a big stock grant, Merck & Co.'s Kenneth Frazier vaulted to the highest echelons of pharma CEO pay last year. With a pay package valued at more than $25 million, Frazier beat out Pfizer's Ian Read and Johnson & Johnson's Alex Gorsky--even if he fell far short of Regeneron chief Len Schleifer.

Takeda names U.S. head, currently its sole female executive

Ramona Sequeira has been named president of Takeda Pharmaceutical's U.S. subsidiary, Takeda Pharmaceuticals U.S.A., reporting directly to President and CEO Christophe Weber, effective June 1. Sequeira is currently a vice president of Eli Lilly.

Valeant CEO's 2014 pay pales in comparison to new EVP's $50M-plus

Valeant Pharmaceuticals CEO J. Michael Pearson took down more than $10 million last year, including a whopping $8 million in incentive pay. But the real surprises in the company's 2015 proxy statement are farther down the chart.

Actavis chairman joins Zoetis board under deal with activist investor Ackman

Pfizer spinoff Zoetis, the animal health company, added a second director to its board under a deal it reached earlier this year with activist investor Bill Ackman and his firm Pershing Square Capital Management.